Oscotec (039200) Fundamentals 2026 — P/E 20.1x, Revenue Analysis | SniperIQ
Oscotec (039200) is a KR-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₩1.12T, trading at ₩29300.00 on the KOE. This SniperIQ fundamentals page covers Oscotec's valuation (P/E 20.1x, P/B 6.3x), profitability (net margin 54.9%), revenue (₩99.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Oscotec's market cap?
Oscotec (039200) has a market capitalization of approximately ₩1.12T, trading at ₩29300.00 on the KOE. Market cap moves with the live share price.
What is Oscotec's P/E ratio?
Oscotec's trailing twelve-month P/E ratio is 20.1x, with a price-to-book (P/B) of 6.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Oscotec?
Oscotec runs a net profit margin of 54.9%, a gross margin of 97.6%, and an operating margin of 49.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Oscotec generate?
Oscotec reported revenue of ₩99.8B for fiscal year 2025, with net income of ₩52.6B and earnings per share (EPS) of 1368.38. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Oscotec pay a dividend?
Oscotec does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Oscotec financially healthy?
Oscotec carries a debt-to-equity ratio of 0.09x and a current ratio of 5.37x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Oscotec a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Oscotec (039200) the key facts are: market cap ₩1.12T, P/E 20.1x, revenue ₩99.8B, 52-week range 27300-66000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Oscotec's full fundamentals live
Get Oscotec's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.